Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration

D. R. Abernethy, I. W. Wainer, J. A. Longstreth, N. S. Andrawis

Research output: Contribution to journalArticle

Abstract

Stereoselective verapamil disposition and dynamics were evaluated after racemic verapamil administration of single i.v. doses, simulated steady- state intravenous infusions, chronic (1 week) administration of oral immediate-release tablets (120 mg three times daily) and chronic (1 week) administration of oral sustained-release tablets (240 mg once daily) to 15 young (mean ± S.E.M. age 22 ± 1 year) and 15 older (69 ± 1 year) healthy male volunteers. After single i.v. doses S-verapamil clearance (young, 102 ± 6 vs. older, 77 ± 6 l/hr; P <.01) and R-verapamil clearance (young, 61 ± 3 vs. older, 45 ± 3 l/hr; P <.01) were similarly decreased. Electrocardiographic P-R prolongation using S-verapamil concentrations and an E(max) model (young E(max), 69 ± 8 vs. older, 42 ± 6 msec; P <.05: young EC50, 15 ± 1 vs. older, 23 ± 3 ng/ml; P <.05) was greater in the young. Simulated steady-state i.v. S-verapamil clearance (young, 76 ± 3 vs. older, 49 ± 2 l/hr; P <.01) and R-verapamil clearance (young, 47 ± 2 vs. older, 28 ± 1 l/hr; P <.01) were similarly less in older subjects and this was unrelated to infusion rate. Qualitatively similar findings were observed during chronic oral (immediate release) treatment and chronic oral (sustained release) treatment. Plasma protein binding of S-verapamil was less in both groups (young, 8.5 ± 0.4 and older, 8.0 ± 0.5% unbound) than that of R- verapamil (young, 5.4 ± 0.2 and older, 5.1 ± 0.3% unbound) and not different between groups. Clearance of both pharmacologically active S- verapamil and R-verapamil is less in older subjects after nonsteady-state and steady-state i.v. and oral racemic verapamil administration. Verapamil- induced cardiac A-V nodal conduction delay is greater in young subjects and this is not due to age-related stereoselective verapamil disposition.

Original languageEnglish (US)
Pages (from-to)904-911
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume266
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Verapamil
Tablets
Oral Administration
Protein S
Intravenous Infusions
Protein Binding
Blood Proteins
Healthy Volunteers

ASJC Scopus subject areas

  • Pharmacology

Cite this

Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. / Abernethy, D. R.; Wainer, I. W.; Longstreth, J. A.; Andrawis, N. S.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 266, No. 2, 1993, p. 904-911.

Research output: Contribution to journalArticle

Abernethy, D. R. ; Wainer, I. W. ; Longstreth, J. A. ; Andrawis, N. S. / Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration. In: Journal of Pharmacology and Experimental Therapeutics. 1993 ; Vol. 266, No. 2. pp. 904-911.
@article{f8dd9ca4e7644ea58a3b507e3ff78950,
title = "Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration",
abstract = "Stereoselective verapamil disposition and dynamics were evaluated after racemic verapamil administration of single i.v. doses, simulated steady- state intravenous infusions, chronic (1 week) administration of oral immediate-release tablets (120 mg three times daily) and chronic (1 week) administration of oral sustained-release tablets (240 mg once daily) to 15 young (mean ± S.E.M. age 22 ± 1 year) and 15 older (69 ± 1 year) healthy male volunteers. After single i.v. doses S-verapamil clearance (young, 102 ± 6 vs. older, 77 ± 6 l/hr; P <.01) and R-verapamil clearance (young, 61 ± 3 vs. older, 45 ± 3 l/hr; P <.01) were similarly decreased. Electrocardiographic P-R prolongation using S-verapamil concentrations and an E(max) model (young E(max), 69 ± 8 vs. older, 42 ± 6 msec; P <.05: young EC50, 15 ± 1 vs. older, 23 ± 3 ng/ml; P <.05) was greater in the young. Simulated steady-state i.v. S-verapamil clearance (young, 76 ± 3 vs. older, 49 ± 2 l/hr; P <.01) and R-verapamil clearance (young, 47 ± 2 vs. older, 28 ± 1 l/hr; P <.01) were similarly less in older subjects and this was unrelated to infusion rate. Qualitatively similar findings were observed during chronic oral (immediate release) treatment and chronic oral (sustained release) treatment. Plasma protein binding of S-verapamil was less in both groups (young, 8.5 ± 0.4 and older, 8.0 ± 0.5{\%} unbound) than that of R- verapamil (young, 5.4 ± 0.2 and older, 5.1 ± 0.3{\%} unbound) and not different between groups. Clearance of both pharmacologically active S- verapamil and R-verapamil is less in older subjects after nonsteady-state and steady-state i.v. and oral racemic verapamil administration. Verapamil- induced cardiac A-V nodal conduction delay is greater in young subjects and this is not due to age-related stereoselective verapamil disposition.",
author = "Abernethy, {D. R.} and Wainer, {I. W.} and Longstreth, {J. A.} and Andrawis, {N. S.}",
year = "1993",
language = "English (US)",
volume = "266",
pages = "904--911",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Stereoselective verapamil disposition and dynamics in aging during racemic verapamil administration

AU - Abernethy, D. R.

AU - Wainer, I. W.

AU - Longstreth, J. A.

AU - Andrawis, N. S.

PY - 1993

Y1 - 1993

N2 - Stereoselective verapamil disposition and dynamics were evaluated after racemic verapamil administration of single i.v. doses, simulated steady- state intravenous infusions, chronic (1 week) administration of oral immediate-release tablets (120 mg three times daily) and chronic (1 week) administration of oral sustained-release tablets (240 mg once daily) to 15 young (mean ± S.E.M. age 22 ± 1 year) and 15 older (69 ± 1 year) healthy male volunteers. After single i.v. doses S-verapamil clearance (young, 102 ± 6 vs. older, 77 ± 6 l/hr; P <.01) and R-verapamil clearance (young, 61 ± 3 vs. older, 45 ± 3 l/hr; P <.01) were similarly decreased. Electrocardiographic P-R prolongation using S-verapamil concentrations and an E(max) model (young E(max), 69 ± 8 vs. older, 42 ± 6 msec; P <.05: young EC50, 15 ± 1 vs. older, 23 ± 3 ng/ml; P <.05) was greater in the young. Simulated steady-state i.v. S-verapamil clearance (young, 76 ± 3 vs. older, 49 ± 2 l/hr; P <.01) and R-verapamil clearance (young, 47 ± 2 vs. older, 28 ± 1 l/hr; P <.01) were similarly less in older subjects and this was unrelated to infusion rate. Qualitatively similar findings were observed during chronic oral (immediate release) treatment and chronic oral (sustained release) treatment. Plasma protein binding of S-verapamil was less in both groups (young, 8.5 ± 0.4 and older, 8.0 ± 0.5% unbound) than that of R- verapamil (young, 5.4 ± 0.2 and older, 5.1 ± 0.3% unbound) and not different between groups. Clearance of both pharmacologically active S- verapamil and R-verapamil is less in older subjects after nonsteady-state and steady-state i.v. and oral racemic verapamil administration. Verapamil- induced cardiac A-V nodal conduction delay is greater in young subjects and this is not due to age-related stereoselective verapamil disposition.

AB - Stereoselective verapamil disposition and dynamics were evaluated after racemic verapamil administration of single i.v. doses, simulated steady- state intravenous infusions, chronic (1 week) administration of oral immediate-release tablets (120 mg three times daily) and chronic (1 week) administration of oral sustained-release tablets (240 mg once daily) to 15 young (mean ± S.E.M. age 22 ± 1 year) and 15 older (69 ± 1 year) healthy male volunteers. After single i.v. doses S-verapamil clearance (young, 102 ± 6 vs. older, 77 ± 6 l/hr; P <.01) and R-verapamil clearance (young, 61 ± 3 vs. older, 45 ± 3 l/hr; P <.01) were similarly decreased. Electrocardiographic P-R prolongation using S-verapamil concentrations and an E(max) model (young E(max), 69 ± 8 vs. older, 42 ± 6 msec; P <.05: young EC50, 15 ± 1 vs. older, 23 ± 3 ng/ml; P <.05) was greater in the young. Simulated steady-state i.v. S-verapamil clearance (young, 76 ± 3 vs. older, 49 ± 2 l/hr; P <.01) and R-verapamil clearance (young, 47 ± 2 vs. older, 28 ± 1 l/hr; P <.01) were similarly less in older subjects and this was unrelated to infusion rate. Qualitatively similar findings were observed during chronic oral (immediate release) treatment and chronic oral (sustained release) treatment. Plasma protein binding of S-verapamil was less in both groups (young, 8.5 ± 0.4 and older, 8.0 ± 0.5% unbound) than that of R- verapamil (young, 5.4 ± 0.2 and older, 5.1 ± 0.3% unbound) and not different between groups. Clearance of both pharmacologically active S- verapamil and R-verapamil is less in older subjects after nonsteady-state and steady-state i.v. and oral racemic verapamil administration. Verapamil- induced cardiac A-V nodal conduction delay is greater in young subjects and this is not due to age-related stereoselective verapamil disposition.

UR - http://www.scopus.com/inward/record.url?scp=0027440330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027440330&partnerID=8YFLogxK

M3 - Article

C2 - 8355215

AN - SCOPUS:0027440330

VL - 266

SP - 904

EP - 911

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -